Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults

Exclusion Criteria

• •Other medical or psychiatric condition may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
• •Participant is expected to require more than 21 days of treatment
• •Participants who need more than 3 systemic antibiotics as part of best available treatment (BAT)
• •Previous administration with an investigational drug within 30 days or 5 half lives preceding the first dose of study intervention used in this study (whichever is longer).
• •Participant is pregnant or breastfeeding.
• •Acute Physiology and Chronic Health Evaluation (APACHE) II score \>30 or \<10 using the most recent available data.